ES2160601T3 - Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina. - Google Patents

Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.

Info

Publication number
ES2160601T3
ES2160601T3 ES93922357T ES93922357T ES2160601T3 ES 2160601 T3 ES2160601 T3 ES 2160601T3 ES 93922357 T ES93922357 T ES 93922357T ES 93922357 T ES93922357 T ES 93922357T ES 2160601 T3 ES2160601 T3 ES 2160601T3
Authority
ES
Spain
Prior art keywords
type
group
protein
streptococes
streptococo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93922357T
Other languages
English (en)
Inventor
Harold J Jennings
Dennis L Kasper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Brigham and Womens Hospital Inc
Original Assignee
National Research Council of Canada
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26823688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2160601(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by National Research Council of Canada, Brigham and Womens Hospital Inc filed Critical National Research Council of Canada
Application granted granted Critical
Publication of ES2160601T3 publication Critical patent/ES2160601T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA INVENCION SE REFIERE A MOLECULAS CONJUGADAS ANTIGENICAS QUE COMPRENDEN EL POLISACARIDO CAPSULAR DE LOS ESTREPTOCOCOS GRUPO B TIPO II LOS CUALES ESTAN ENLAZADOS DE MODO COVALENTE CON LA PROTEINA. ESTA INVENCION SE REFIERE ADEMAS A MOLECULAS CONJUGADAS ANTIGENICAS QUE COMPRENDEN EL POLISACARIDO CAPSULAR DE LOS ESTREPTOCOCOS GRUPO B TIPO V LOS CUALES ESTAN ENLAZADOS DE MODO COVALENTE CON LA PROTEINA. ESTA INVENCION TAMBIEN SE REFIERE A VACUNAS Y METODOS DE INMUNIZACION DE MAMIFEROS, INCLUYENDO A LAS PERSONAS CONTRA LA INFECCION POR ESTREPTOCOCOS GRUPO B TIPO II (GBS II) Y/O ESTREPTOCOCOS GRUPO B TIPO V (GBS V). TAMBIEN SON REIVINDICADAS LAS VACUNAS MULTIVALENTES LAS CUALES COMPRENDEN LAS MOLECULAS CONJUGADAS DE ESTA INVENCION Y LOS ANTIGENOS PARA OTRAS BACTERIAS PATOGENICAS.
ES93922357T 1992-09-24 1993-09-24 Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina. Expired - Lifetime ES2160601T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94997092A 1992-09-24 1992-09-24
US12555693A 1993-09-23 1993-09-23

Publications (1)

Publication Number Publication Date
ES2160601T3 true ES2160601T3 (es) 2001-11-16

Family

ID=26823688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93922357T Expired - Lifetime ES2160601T3 (es) 1992-09-24 1993-09-24 Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.

Country Status (16)

Country Link
US (2) US5795580A (es)
EP (1) EP0667787B1 (es)
JP (3) JP4163251B2 (es)
KR (1) KR100293017B1 (es)
AT (1) ATE203167T1 (es)
AU (1) AU690525B2 (es)
CA (1) CA2145397C (es)
DE (1) DE69330464T2 (es)
DK (1) DK0667787T3 (es)
ES (1) ES2160601T3 (es)
FI (1) FI110993B (es)
GR (1) GR3036928T3 (es)
IL (1) IL107103A (es)
NO (2) NO319569B1 (es)
NZ (2) NZ299249A (es)
PT (1) PT667787E (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719677T2 (de) * 1996-11-18 2003-09-18 Japan Storage Battery Co. Ltd., Kyoto Positivelektrode für Lithiumbatterie und Lithiumbatterie
AU763349B2 (en) * 1998-02-05 2003-07-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DK1320542T3 (da) 2000-08-08 2007-09-10 St Jude Childrens Res Hospital Gruppe B streptokokpolypeptider-nukleinsyrer og terapeutiske sammensætninger og vacciner deraf
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
CA2520865A1 (en) * 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
CA2530363C (en) * 2003-06-23 2013-05-07 Baxter International Inc. Carrier proteins for vaccines
CN101107010A (zh) * 2004-11-01 2008-01-16 布里格海姆妇女医院公司 经修饰的链球菌多糖及其用途
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
WO2007092451A2 (en) * 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有ｐｓａ組成物、その単離の方法および使用の方法
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
IL255106B2 (en) * 2015-05-04 2023-04-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
JP2022532142A (ja) * 2019-05-10 2022-07-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム コンジュゲートの製造

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4207414A (en) * 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
IE51174B1 (en) * 1980-04-14 1986-10-29 Merck & Co Inc Group b streptococcal capsular polysaccharides
US4438261A (en) * 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4367222A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4367221A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4356263A (en) * 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4367223A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4284537A (en) * 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) * 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
DE3750139T2 (de) * 1986-04-16 1994-10-06 Brigham & Womens Hospital Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
EP0419462A4 (en) * 1987-07-17 1991-07-17 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
WO1991008772A1 (en) * 1989-12-14 1991-06-27 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
GR3036928T3 (en) 2002-01-31
CA2145397C (en) 2007-10-30
ATE203167T1 (de) 2001-08-15
EP0667787A1 (en) 1995-08-23
KR100293017B1 (ko) 2001-09-17
AU690525B2 (en) 1998-04-30
FI110993B (fi) 2003-05-15
NO951152D0 (no) 1995-03-24
NO951109D0 (no) 1995-03-23
JPH08501563A (ja) 1996-02-20
NZ299249A (en) 2000-08-25
KR950703361A (ko) 1995-09-20
PT667787E (pt) 2001-10-31
AU5137893A (en) 1994-04-12
DE69330464T2 (de) 2001-11-08
FI951412A0 (fi) 1995-03-24
EP0667787B1 (en) 2001-07-18
DE69330464D1 (en) 2001-08-23
JP4308174B2 (ja) 2009-08-05
IL107103A0 (en) 1994-08-26
NO319569B1 (no) 2005-08-29
US5795580A (en) 1998-08-18
DK0667787T3 (da) 2001-10-29
JP2009132727A (ja) 2009-06-18
IL107103A (en) 2001-03-19
JP2005306884A (ja) 2005-11-04
JP4163251B2 (ja) 2008-10-08
FI951412L (fi) 1995-05-24
NO951109L (no) 1995-05-22
US5993825A (en) 1999-11-30
CA2145397A1 (en) 1994-03-31
NZ248766A (en) 1996-11-26

Similar Documents

Publication Publication Date Title
ES2160601T3 (es) Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
BR9106748A (pt) Vacina de hyopneumomiae micoplasma inativado e metodo de seu uso
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ES2164251T3 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
NO20015073L (no) Vaksiner
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
NL980007I1 (nl) Acellulair vaccin.
ES2100893T3 (es) Procedimiento de preparacion de una vacuna o de un agente toxico.
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
CO5241277A1 (es) Vacuna

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 667787

Country of ref document: ES